Cargando…
EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?
Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, catalyzes tri-methylation of histone H3 at Lys 27 (H3K27me3) to regulate gene expression through epigenetic machinery. EZH2 functions as a double-facet molecule in regulation of gene expression via repression or activation mechanisms,...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485996/ https://www.ncbi.nlm.nih.gov/pubmed/28561778 http://dx.doi.org/10.3390/ijms18061172 |
_version_ | 1783246175418187776 |
---|---|
author | Yan, Ke-Sin Lin, Chia-Yuan Liao, Tan-Wei Peng, Cheng-Ming Lee, Shou-Chun Liu, Yi-Jui Chan, Wing P. Chou, Ruey-Hwang |
author_facet | Yan, Ke-Sin Lin, Chia-Yuan Liao, Tan-Wei Peng, Cheng-Ming Lee, Shou-Chun Liu, Yi-Jui Chan, Wing P. Chou, Ruey-Hwang |
author_sort | Yan, Ke-Sin |
collection | PubMed |
description | Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, catalyzes tri-methylation of histone H3 at Lys 27 (H3K27me3) to regulate gene expression through epigenetic machinery. EZH2 functions as a double-facet molecule in regulation of gene expression via repression or activation mechanisms, depending on the different cellular contexts. EZH2 interacts with both histone and non-histone proteins to modulate diverse physiological functions including cancer progression and malignancy. In this review article, we focused on the updated information regarding microRNAs (miRNAs) and long non coding RNAs (lncRNAs) in regulation of EZH2, the oncogenic and tumor suppressive roles of EZH2 in cancer progression and malignancy, as well as current pre-clinical and clinical trials of EZH2 inhibitors. |
format | Online Article Text |
id | pubmed-5485996 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-54859962017-06-29 EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe? Yan, Ke-Sin Lin, Chia-Yuan Liao, Tan-Wei Peng, Cheng-Ming Lee, Shou-Chun Liu, Yi-Jui Chan, Wing P. Chou, Ruey-Hwang Int J Mol Sci Review Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, catalyzes tri-methylation of histone H3 at Lys 27 (H3K27me3) to regulate gene expression through epigenetic machinery. EZH2 functions as a double-facet molecule in regulation of gene expression via repression or activation mechanisms, depending on the different cellular contexts. EZH2 interacts with both histone and non-histone proteins to modulate diverse physiological functions including cancer progression and malignancy. In this review article, we focused on the updated information regarding microRNAs (miRNAs) and long non coding RNAs (lncRNAs) in regulation of EZH2, the oncogenic and tumor suppressive roles of EZH2 in cancer progression and malignancy, as well as current pre-clinical and clinical trials of EZH2 inhibitors. MDPI 2017-05-31 /pmc/articles/PMC5485996/ /pubmed/28561778 http://dx.doi.org/10.3390/ijms18061172 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Yan, Ke-Sin Lin, Chia-Yuan Liao, Tan-Wei Peng, Cheng-Ming Lee, Shou-Chun Liu, Yi-Jui Chan, Wing P. Chou, Ruey-Hwang EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe? |
title | EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe? |
title_full | EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe? |
title_fullStr | EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe? |
title_full_unstemmed | EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe? |
title_short | EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe? |
title_sort | ezh2 in cancer progression and potential application in cancer therapy: a friend or foe? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485996/ https://www.ncbi.nlm.nih.gov/pubmed/28561778 http://dx.doi.org/10.3390/ijms18061172 |
work_keys_str_mv | AT yankesin ezh2incancerprogressionandpotentialapplicationincancertherapyafriendorfoe AT linchiayuan ezh2incancerprogressionandpotentialapplicationincancertherapyafriendorfoe AT liaotanwei ezh2incancerprogressionandpotentialapplicationincancertherapyafriendorfoe AT pengchengming ezh2incancerprogressionandpotentialapplicationincancertherapyafriendorfoe AT leeshouchun ezh2incancerprogressionandpotentialapplicationincancertherapyafriendorfoe AT liuyijui ezh2incancerprogressionandpotentialapplicationincancertherapyafriendorfoe AT chanwingp ezh2incancerprogressionandpotentialapplicationincancertherapyafriendorfoe AT chourueyhwang ezh2incancerprogressionandpotentialapplicationincancertherapyafriendorfoe |